Advances in the Therapeutic Landscape of Anti-MAG Neuropathy

episode

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A Powerful Nor'easter Pummels the East Coast 3 min · 26 Sep 2026 · Fox News Hourly Update

NPR News: 09-26-2026 1PM EDT 4 min · 26 Sep 2026 · NPR News Now

SLOVENIA V SCOTLAND OPENLINE | SATURDAY 26TH SEPTEMBER 45 min · 26 Sep 2026 · Superscoreboard

Tug of War At Labour Conference 35 min · 26 Sep 2026 · Newscast

SLOVENIA 0-0 SCOTLAND | SATURDAY 26TH SEPTEMBER 2h 3m · 26 Sep 2026 · Superscoreboard

UPDATES From Your Favorite Stories! | Reading Reddit Stories 1h 23m · 26 Sep 2026 · Smosh Reads Reddit Stories

Report any issue

Source

Recorded30 Sep 2024

Publisheranchor.fm ↗

Handlerec:820422

Show notes

Despite its recognition for nearly 40 years, anti-MAG neuropathy continues to have limited therapeutic options. The emergence of bruton tyrosine kinase inhibition as a new therapeutic pathway appears promising. In this interview, Dr. Amro Stino interviews Dr. Chiara Briani on her 2023 paper exploring the prevalence of the MYD 88 mutation among patients with anti-MAG neuropathy. This is discussed within the broader context of disease presentation, current treatment landscape, and future drug development.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in